| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
(8-epi)-BW 245C targets the Prostaglandin D2 (PGD2) receptors, specifically the DP1 receptor (also known as the DP receptor). It acts as a selective agonist for the DP receptor. The activity of BW 245C (the parent compound) is approximately 70-fold greater than that of (8-epi)-BW 245C, demonstrating that the stereochemistry at the C-8 position is critical for high-affinity DP receptor interaction.
|
|---|---|
| ln Vitro |
(8-epi)-BW 245C is a PGD2 receptor agonist with significantly less potency compared to its epimer, BW 245C. The potency of BW 245C is reported to be 70-fold higher than that of (8-epi)-BW 245C (BW 246C). This makes it an important negative control or tool for studying the structural requirements for DP1 receptor activation.
|
| ln Vivo |
Specific in vivo activity data for (8-epi)-BW 245C has not been published. The high-affinity epimer, BW 245C, is known to induce vasodilation, inhibit platelet aggregation, and regulate sleep in vivo. As (8-epi)-BW 245C is less active, it would likely require much higher doses to produce similar effects, or it may act as a partial agonist.
|
| Enzyme Assay |
The specific protocol for in vitro receptor binding would use radioligand displacement assays with membranes expressing human DP1 receptors. The membranes are incubated with [3H]-PGD2 as the radioligand. A dilution series of (8-epi)-BW 245C and BW 245C (as a positive control) are added simultaneously. After incubation and filtration, the radioactivity is measured to calculate the IC50 and Ki. Comparison of the Ki values between the two diastereomers quantifies the "activity loss" due to the epimerization.
|
| Cell Assay |
In an in vitro functional cell-based assay, CHO cells stably expressing the human DP1 receptor and a cAMP-responsive luciferase reporter are utilized. Cells are seeded in 96-well plates. The next day, cells are stimulated with increasing concentrations of (8-epi)-BW 245C (0.1 nM to 10 uM) for 4-6 hours. The DP1 receptor couples to Gs, leading to an increase in intracellular cAMP. Luciferase activity, which is proportional to cAMP accumulation, is measured. The EC50 is calculated and compared to the EC50 of BW 245C to assess relative efficacy and potency.
|
| Animal Protocol |
There are no standard in vivo protocols specific to (8-epi)-BW 245C. For the active epimer, a common protocol involves measuring platelet aggregation. Platelet-rich plasma (PRP) is prepared from human or rodent blood. The change in light transmission is measured in an aggregometer. (8-epi)-BW 245C would be added to the cuvette at concentrations up to 10 uM to measure its ability (or lack thereof) to inhibit ADP-induced platelet aggregation, compared to the active epimer.
|
| ADME/Pharmacokinetics |
Published pharmacokinetic parameters for (8-epi)-BW 245C are not available. As a small peptide-like or lipid analog, its half-life is expected to be short due to rapid metabolism. The pharmacokinetic profile would be studied using radiolabeled tracer material if necessary. Its role as a less active control means it is seldom characterized in PK studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for (8-epi)-BW 245C is not available. As a research chemical used in low concentrations, it is expected to have minimal toxicity. However, high doses could potentially cause side effects related to DP1 receptor activation, such as vasodilation (flushing, hypotension) or nasal congestion, though significantly higher doses would be required compared to BW 245C to achieve these effects.
|
| References | |
| Additional Infomation |
7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-yl]heptanoic acid is an imidazolidine-2,4-dione with the structure 7-(2,5-dioxoimidazolidine-4-yl)heptanoic acid, wherein the 3-position of the imidazoline ring is substituted with a 3-(3-cyclohexyl-3-hydroxypropyl) group. It is an imidazolidine-2,4-dione, a secondary alcohol, and a monocarboxylic acid.
(8-epi)-BW 245C is exclusively a research chemical and is not approved for clinical use. It is used primarily as an analytical reference standard and as a structure-activity relationship (SAR) tool. By comparing the binding of (8-epi)-BW 245C (inactive) to BW 245C (active), researchers can validate that biological effects are specifically mediated via the DP1 receptor and not due to non-specific interactions or impurities. |
| Molecular Formula |
C19H32N2O5
|
|---|---|
| Molecular Weight |
368.47
|
| Exact Mass |
368.231
|
| CAS # |
65705-83-1
|
| Related CAS # |
BW 245C;72814-32-5
|
| PubChem CID |
119304
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.521
|
| LogP |
2.12
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
26
|
| Complexity |
490
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCC(CC1)C(CCN2C(C(=O)NC2=O)CCCCCCC(=O)O)O
|
| InChi Key |
ZIDQIOZJEJFMOH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H32N2O5/c22-16(14-8-4-3-5-9-14)12-13-21-15(18(25)20-19(21)26)10-6-1-2-7-11-17(23)24/h14-16,22H,1-13H2,(H,23,24)(H,20,25,26)
|
| Chemical Name |
7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7139 mL | 13.5696 mL | 27.1393 mL | |
| 5 mM | 0.5428 mL | 2.7139 mL | 5.4279 mL | |
| 10 mM | 0.2714 mL | 1.3570 mL | 2.7139 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
